Press Releases
Sep 19, 2022

Sponsorship provides a year of access to MBC BioLabs' life-science incubators and in-house Astellas expertise for scientific innovators TOKYO and SAN FRANCISCO, Sept. 19, 2022 /PRNewswire/ --...

Sep 12, 2022

– Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab – – Data highlighted in...

Sep 4, 2022

Clinical trial evaluated the safety and tolerability of 30 mg dose for the treatment of vasomotor symptoms (VMS) associated with menopause TOKYO, Sept. 4, 2022 /PRNewswire/ -- Astellas Pharma Inc....


Sep 20, 2022

Astellas was recently ranked in Seramount’s 2022 list of 100 Best Companies and Best Companies for Dads highlighting our commitment to creating a workplace where working parents are valued and...

Sep 20, 2022

Astellas ranked again in Seramount’s 2022 “100 Best Companies” list and Best Companies for Dads

Sep 13, 2022

C3 Prize Winner Shares How Her Father’s Experience with Cancer Inspired Her to Create New Patient App Astellas Pharma senior vice president and global head of Patient Centricity Dr. Anthony...


Stay Connected

Get only the email alerts you want.


Media Contacts


For media inquiries and reporter requests, please click here to fill out a request form.

Our communications team will respond to verified media requests within 24-48 hours as appropriate.

If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.


Astellas on Twitter
Download Fact Sheet
Explore U.S. Products